Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

You may be able to join if

• ≥5 to <18 years of age, inclusive.
• Diagnosis of jPsA by Vancouver inclusion criteria, with exclusion of ERA. Diagnosis made ≥3 months (ie. 90 days) prior to screening. Arthritis plus psoriasis, or arthritis plus ≥2 of the following: dactylitis, nail pits, family history of psoriasis in a first- or second-degree relative, psoriasis-like rash.
• Active disease in ≥3 joints at screening and at Week 0 (defined as swelling or loss of motion with pain and/or tenderness). Swelling alone meets the criteria for an active arthritic joint. In the absence of swelling, loss of motion with pain or tenderness or both pain and tenderness meet the criteria for an active arthritic joint
• Have active disease despite previous non-biologic DMARD and/or NSAID therapy: • Non-biologic DMARD therapy is defined as taking a non-biologic DMARD for at least 12 weeks or evidence of intolerance. • NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of intolerance.
• If previously treated with an anti-TNFα agent (such as adalimumab, etanercept, infliximab, golimumab [SC or IV], certolizumab pegol, or their respective biosimilars) or other biologic agents that are not included in the exclusion criteria, these agents should have been discontinued taking into consideration their elimination half-life, dosing frequency and acceptable clinical practice, before first study intervention administration (see Appendix 7 [Section 10.7] for Table 7 with the required minimal washout period for a specific prior treatment). Refer to Appendix 18 (Section 10.18.1) for country-specific requirements in France for the required minimum washout periods for Anti-TNFα agents.